Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 159,588 251,929 319,053 656,089
Total Sell Value $13,270,852 $21,508,551 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 10 19 27 56
End Date 2024-03-24 2023-12-22 2023-06-23 2022-06-23

   
Records found: 1303
  Page 51 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Swiedler Stuart J SVP, Clinical Affairs   •       –      –    2006-08-01 4 AS $14.34 $179,188 D/D (12,500) 10,000     -
   Swiedler Stuart J SVP, Clinical Affairs   •       –      –    2006-08-01 4 OE $4.00 $50,000 D/D 12,500 22,500     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2006-08-01 4 AB $14.50 $21,750 D/D 1,500 30,881     -
   Heron Elaine J Director   –       •      –    2006-07-19 4 OE $4.72 $94,400 D/D 20,000 20,000     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2006-07-03 4 AB $14.44 $21,660 D/D 1,500 29,381     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2006-06-14 4 B $13.15 $33,090 D/D 2,500 27,881 2.81     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2006-06-01 4 AB $13.05 $19,575 D/D 1,500 25,381     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2006-05-18 4 B $12.00 $12,000 D/D 1,000 23,881 2.81     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2006-05-08 4 B $12.78 $12,778 D/D 1,000 22,881 2.81     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2006-05-01 4 AB $12.55 $18,880 D/D 1,500 18,500     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2006-04-28 4 A $6.92 $23,393 D/D 3,381 21,881     -
   Kakkis Emil D Chief Medical Officer   •       –      –    2006-04-28 4 A $3.43 $14,430 D/D 4,202 33,776     -
   Baffi Robert SVP, Technical Operations   •       –      –    2006-04-28 4 A $3.43 $13,039 D/D 3,797 26,546     -
   Aselage Steve SVP, Global Commercial Ops   •       –      –    2006-04-28 4 A $6.92 $6,635 D/D 959 959     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2006-04-03 4 AB $13.33 $20,019 D/D 1,500 17,000     -
   Cooper Jeffrey H Chief Financial Officer   •       –      –    2006-03-16 4 AS $14.85 $185,625 D/D (12,500) 0     -
   Cooper Jeffrey H Chief Financial Officer   •       –      –    2006-03-16 4 OE $8.10 $101,250 D/D 12,500 12,500     -
   Cooper Jeffrey H Chief Financial Officer   •       –      –    2006-03-01 4 AS $13.25 $205,375 D/D (15,500) 0     -
   Cooper Jeffrey H Chief Financial Officer   •       –      –    2006-03-01 4 OE $5.15 $93,055 D/D 15,500 13,500     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2006-03-01 4 AB $12.96 $19,490 D/D 1,500 15,500     -
   Cooper Jeffrey H Chief Financial Officer   •       –      –    2006-02-27 4 AS $13.25 $13,250 D/D (1,000) 0     -
   Cooper Jeffrey H Chief Financial Officer   •       –      –    2006-02-27 4 OE $5.15 $5,150 D/D 1,000 1,000     -
   Lapalme Pierre Director   –       •      –    2006-02-27 4 B $12.97 $45,456 D/D 3,500 3,500 2.39     -
   Sager Erich Director   –       •      –    2006-02-24 4 AS $12.64 $145,360 D/D (11,500) 3,309     -
   Sager Erich Director   –       •      –    2006-02-24 4 OE $7.00 $80,500 D/D 11,500 14,809     -
  1303 Records found
  Previous  50  51  52  53   
  Page 51 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us